Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle

Veterinary Ophthalmology

Volumn 7, Issue 1, 2004, Pages 53-57

  Gelatt, Kirk N ^a   MacKay, Edward O ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

Dog; Glaucoma; Prostaglandin; Travoprost

Indexed keywords

CLOPROSTENOL; DRUG DERIVATIVE; EYE DROPS; METHYLCELLULOSE; PROSTAGLANDIN F; TRAVOPROST;

ANIMAL; ANIMAL DISEASE; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG ADMINISTRATION; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; GLAUCOMA; HOSPITALIZATION; INTRAOCULAR PRESSURE; MALE; MANOMETRY; MIOSIS; MULTIPLE DRUG DOSE; NONHUMAN; PATHOLOGY; PUPIL; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY; TONOMETRY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CLOPROSTENOL; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MANOMETRY; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; PUPIL; SEVERITY OF ILLNESS INDEX;

ANIMALIA; CANIS FAMILIARIS;

EID: 1342300780     PISSN: 14635216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2004.00326.x     Document Type: Article

References (39)

1. Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Survey Ophthalmology 2002; 47: S2-S5.
2. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. American Journal of Ophthalmology 2002; 134: 749-760.
3. Higginbotham EJ. (ed.) Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? Archives of Ophthalmology 1996; 114: 998-999.
4. Wyse TB, Talluto DM, Krupin T et al. Topical prostaglandins for glaucoma therapy. Journal of Glaucoma 1997; 6: 180-187.
5. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new intriguing side effect. Survey of Ophthalmology 1997; 41 (Suppl. 2): S1-S14.
6. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology 1995; 102: 1743-1752.
7. Susanna R, Giampani J, Borges AS et al. A double-masked randomized clinical trail comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001; 108: 259-263.
8. Gandolfi S, Simmons ST, Sturm R et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Advances in Therapy 2001; 18: 110-121.
9. Zhan GL, Toris CB, Camras CB et al. Prostaglandin-induced iris color darkening. Archives of Ophthalmology 1998; 116: 1065-1068.
10. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridal pigmentation in primates. Survey of Ophthalmology 1997; 41 (Suppl.): S125-S128.
11. Zhan GL, Toris CB, Camras CB et al. Prostaglandin-induced iris color darkening. Archives of Ophthalmology 1998; 116: 1065-1068.
12. 2α on aqueous humor dynamics of rabbit, cat, and monkey. Investigative Ophthalmology Visual Science 1984; 25: 1087-1093.
13. Bito LZ, Camras CB, Gum GG, Resul B. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. In: The Ocular Effects of Prostaglandins and Other Eicosanoids. (eds Bito LZ, Stjernschantz J) Alan R Liss, New York, 1989; 349-368.
14. Bito LZ, Fraga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or Rhesus monkey eyes. Investigative Ophthalmology and Visual Science 1983; 24: 312-319.
15. 2 increases uveoscleral outflow and trabecular outflow facility in the cat. Experimental Eye Research 1995; 61: 649-657.
16. 2α on uveoscleral outflow and outflow facility in the rabbit eye. Experimental Eye Research 1992; 54: 277-283.
17. 2α isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes. Journal of Ocular Pharmacology 1991; 7: 107-116.
18. 2α isopropyl ester versus Iloprost phenacyl ester in rabbit and Beagle eyes. Current Eye Research 1989; 8: 131-138.
19. Studer ME, Martin CL, Stiles J. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats. American Journal of Veterinary Research 2000; 61: 1220-1224.
20. Gelatt KN, MacKay EO. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Veterinary Ophthalmology 2001; 4: 283-288.
21. Ofri R, Raz D, Kass PH et al. The effect of 0.12% unoprostone isopropyl (rescula) on intraocular pressure in normotensive dogs. Journal of Veterinary Medical Science 2000; 62: 1313-1315.
22. Gelatt KN, MacKay EO. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Journal of Ocular Pharmacology and Therapeutics 2002; 18: 525-534.
23. Hellberg MR, Sallee VL, McLaughlin MA et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. Journal of Ocular Pharmacology and Therapeutics 2001; 17: 421-432.
24. Hellberg MR, McLaughlin MA, Sharif NA et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Survey of Ophthalmology 2002; 47: S13-S33.
25. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost; a review of recent studies of two new glaucoma drugs. Survey of Ophthalmology 2002; 47: S105-S115.
26. Goldberg I, Cunha-Vaz J, Jakobsen JE et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. Journal of Glaucoma 2001; 10: 414-422.
27. Orengo-Nania S, Landry T, Von Tress M et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. American Journal of Ophthalmology 2001; 132: 860-868.
28. Fellman RL, Sullivan EK, Ratliff M et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter study. Ophthalmology 2002; 109: 998-1008.
29. Netland PA, Landry T, Sullivan EK et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology 2001; 132: 472-484.
30. SAS/STAT. Guide for Personal Computers, Version 6ed, SAS Institute, Inc., Cary, NC.
31. Gelatt KN, Gum GG, Barrie KP, Williams LW. Diurnal variations in intraocular pressure in normotensive and glaucomatous Beagles. Glaucoma 1981; 3: 121-124.
32. Orzalesi N, Rossetti L, Invernizzi T et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Investigative Ophthalmology and Visual Science 2000; 41: 2566-2573.
33. Yoshitomi T, Ito Y. Effects of indomethacin and prostaglandins on the dog iris sphincter and dilator muscles. Investigative Ophthalmology and Visual Science 1988; 29: 127-132.
34. Lu W, Okamura T, Bian K et al. Prostaglandins involved in contractions by angiotension II and bradykinin of isolated dog sphincter pupillae. British Journal of Pharmacology 1988; 95: 544-550.
35. 4 on pupil size, intraocular pressure, and blood-aqueous barrier in dogs. American Journal of Veterinary Research 1992; 53: 1302-1304.
36. Gwin RM, Gelatt KN, Gum GG et al. The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous Beagle. Investigative Ophthalmology and Visual Science 1977; 16: 1135-1142.
37. Gum GG, Gelatt KN, Gelatt JK, Jones R. The effect of topical demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in normal beagles and beagles with inherited glaucoma. American Journal of Veterinary Research 1993; 54: 287-293.
38. Gelatt KN, Larocca RD, Gelatt JK et al. Evaluation of multiple doses of 4% and 6% timolol and timolol combined with 2% pilocarpine in normotensive and glaucomatous beagles. American Journal of Veterinary Research 1995; 56: 1325-1331.
39. King TC, Gum GG, Gelatt KN. Evaluation of a topical carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous beagles. American Journal of Veterinary Research 1991; 52: 2067-2070.